Vergoeding 2017-2021 voor ATC-subgroep A10BH : Dipeptidylpeptidase-4-remmers
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| A10BH01 Sitagliptine (Januvia ®) | 7.499.100 | 8.041.000 | 9.659.400 | 10.544.600 | 10.395.400 |
| A10BH02 Vildagliptine (Galvus ®) | 1.598.900 | 1.473.800 | 1.457.200 | 1.431.000 | 1.228.700 |
| A10BH03 Saxagliptine (Onglyza ®) | 484.410 | 416.150 | 391.220 | 350.210 | 298.080 |
| A10BH05 Linagliptine (Trajenta ®) | 2.364.300 | 2.479.000 | 2.905.300 | 3.279.800 | 3.244.600 |
| Totaal | 11.946.710 | 12.409.950 | 14.413.120 | 15.605.610 | 15.166.780 |